Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas

Next Previous
Trial Profile

An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Pacmilimab (Primary) ; Vemurafenib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Carcinoma; Colon cancer; Colorectal cancer; Gastric cancer; Liver cancer; Lung cancer; Lymphoma; Malignant fibrous histiocytoma; Malignant melanoma; Malignant thymoma; Merkel cell carcinoma; Oesophageal cancer; Pancreatic cancer; Renal cancer; Sarcoma; Skin cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms PROCLAIM-072; PROCLAIM-CX-072; PROCLAIM-CX-072-001
  • Sponsors CytomX Therapeutics

Most Recent Events

  • 07 Feb 2022 Status changed from active, no longer recruiting to completed.
  • 19 Nov 2021 This trial has been completed in Hungary, according to European Clinical Trials Database record.
  • 15 Nov 2021 This trial has been completed in Netherlands, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top